The news: Dexcom and Oura are integrating glucose and biometric data collected by their respective continuous glucose monitor (CGM) and Oura Ring devices.

• In addition to facilitating data sharing, the pair will co-market and cross-sell each other’s products. The duo’s first app integration is expected to launch in the first half of 2025.
• Dexcom will also make a $75 million investment in Oura’s Series D funding.

What it means for Dexcom: The partnership represents Dexcom’s latest endeavor aimed at getting its products into the hands (or arms) of more consumers.

• In June, the company launched its Direct to Apple Watch capability. Using a dedicated Bluetooth connection, Dexcom’s G7 CGM system sends glucose information and personalized alerts directly to a user’s Apple Watch, bypassing the need for iPhones for real-time readings.
• Dexcom also made its over-the-counter (OTC) CGM, Stelo, available for all consumers who want to track their blood sugar, whether or not they’re diabetic.
• Now, Dexcom is joining forces with Oura after an announcement that Oura sold 2.5 million rings and expects to see annual sales double to roughly $500 million in 2024. With interest in smart rings on the rise, Dexcom has an opportunity to get its OTC CGMs in front of Oura’s growing consumer base.